Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
TEVA's Cash-to-Debt is ranked lower than
96% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. TEVA: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
TEVA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.42 Max: N/A
Current: 0.03
Equity-to-Asset 0.37
TEVA's Equity-to-Asset is ranked lower than
83% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. TEVA: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
TEVA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.49 Max: 0.6
Current: 0.37
0.36
0.6
Interest Coverage 4.08
TEVA's Interest Coverage is ranked lower than
83% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 112.31 vs. TEVA: 4.08 )
Ranked among companies with meaningful Interest Coverage only.
TEVA' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 11.22 Max: 20.32
Current: 4.08
3.6
20.32
Piotroski F-Score: 3
Altman Z-Score: 0.83
Beneish M-Score: -2.23
WACC vs ROIC
3.48%
2.67%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 8.29
TEVA's Operating Margin % is ranked higher than
51% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. TEVA: 8.29 )
Ranked among companies with meaningful Operating Margin % only.
TEVA' s Operating Margin % Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 8.29
8.12
25.46
Net Margin % 1.49
TEVA's Net Margin % is ranked lower than
67% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. TEVA: 1.49 )
Ranked among companies with meaningful Net Margin % only.
TEVA' s Net Margin % Range Over the Past 10 Years
Min: 1.49  Med: 12.03 Max: 20.75
Current: 1.49
1.49
20.75
ROE % 0.24
TEVA's ROE % is ranked lower than
69% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. TEVA: 0.24 )
Ranked among companies with meaningful ROE % only.
TEVA' s ROE % Range Over the Past 10 Years
Min: 0.22  Med: 10 Max: 16.18
Current: 0.24
0.22
16.18
ROA % 0.43
TEVA's ROA % is ranked lower than
66% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. TEVA: 0.43 )
Ranked among companies with meaningful ROA % only.
TEVA' s ROA % Range Over the Past 10 Years
Min: 0.43  Med: 4.95 Max: 9.26
Current: 0.43
0.43
9.26
ROC (Joel Greenblatt) % 14.14
TEVA's ROC (Joel Greenblatt) % is ranked higher than
51% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. TEVA: 14.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
TEVA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.14  Med: 33.56 Max: 49.79
Current: 14.14
14.14
49.79
3-Year Revenue Growth Rate -1.60
TEVA's 3-Year Revenue Growth Rate is ranked lower than
73% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. TEVA: -1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
TEVA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 14.9 Max: 37.4
Current: -1.6
-1.6
37.4
3-Year EBITDA Growth Rate -7.20
TEVA's 3-Year EBITDA Growth Rate is ranked lower than
78% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. TEVA: -7.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
TEVA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -10.5  Med: 16.3 Max: 47.3
Current: -7.2
-10.5
47.3
3-Year EPS without NRI Growth Rate -63.90
TEVA's 3-Year EPS without NRI Growth Rate is ranked lower than
98% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. TEVA: -63.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
TEVA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -63.9  Med: 16 Max: 119.7
Current: -63.9
-63.9
119.7
GuruFocus has detected 6 Warning Signs with Teva Pharmaceutical Industries Ltd $TEVA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» TEVA's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

TEVA Guru Trades in Q3 2016

Paul Tudor Jones 5,930 sh (New)
NWQ Managers 2,663,631 sh (+58.75%)
Jim Simons 1,947,963 sh (+40.37%)
Jeremy Grantham 336,700 sh (+17.19%)
Barrow, Hanley, Mewhinney & Strauss 26,570,988 sh (+17.05%)
Michael Price 469,300 sh (+6.59%)
Vanguard Health Care Fund 6,746,400 sh (+6.13%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 542,000 sh (unchged)
John Griffin Sold Out
Ronald Muhlenkamp 175,770 sh (-0.50%)
Keeley Asset Management Corp 56,869 sh (-2.23%)
Manning & Napier Advisors, Inc 113,436 sh (-2.46%)
David Dreman 31,969 sh (-3.92%)
John Paulson 16,076,900 sh (-4.15%)
Richard Snow 965,986 sh (-10.23%)
Andreas Halvorsen 19,684,219 sh (-29.03%)
Larry Robbins 2,176,144 sh (-29.41%)
Signature Select Canadian Fund 40,500 sh (-58.38%)
» More
Q4 2016

TEVA Guru Trades in Q4 2016

Julian Robertson 554,800 sh (New)
David Tepper 5,053,000 sh (New)
Michael Price 696,500 sh (+48.41%)
Ronald Muhlenkamp 239,889 sh (+36.48%)
Vanguard Health Care Fund 8,922,300 sh (+32.25%)
Barrow, Hanley, Mewhinney & Strauss 32,455,432 sh (+22.15%)
Jim Simons 2,165,863 sh (+11.19%)
First Eagle Investment 200 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Larry Robbins Sold Out
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
John Paulson 15,925,800 sh (-0.94%)
Manning & Napier Advisors, Inc 84,033 sh (-25.92%)
David Dreman 16,751 sh (-47.60%)
NWQ Managers 858,877 sh (-67.76%)
Keeley Asset Management Corp 16,603 sh (-70.80%)
Richard Snow 191,703 sh (-80.15%)
Jeremy Grantham 14,950 sh (-95.56%)
Eaton Vance Worldwide Health Sciences Fund 416,622 sh (-23.13%)
» More
Q1 2017

TEVA Guru Trades in Q1 2017

Francis Chou 215,000 sh (New)
Caxton Associates 12,200 sh (New)
Jim Simons 4,817,763 sh (+122.44%)
Vanguard Health Care Fund 11,717,600 sh (+31.33%)
Manning & Napier Advisors, Inc 96,678 sh (+15.05%)
NWQ Managers 926,179 sh (+7.84%)
Michael Price 720,000 sh (+3.37%)
Julian Robertson 557,600 sh (+0.50%)
George Soros 600,000 sh (unchged)
First Eagle Investment 200 sh (unchged)
Steven Cohen 50,000 sh (unchged)
Ray Dalio 24,700 sh (unchged)
Bernard Horn 65,600 sh (unchged)
Jeremy Grantham Sold Out
Signature Select Canadian Fund Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
David Dreman 15,646 sh (-6.60%)
Barrow, Hanley, Mewhinney & Strauss 29,753,982 sh (-8.32%)
John Paulson 10,997,300 sh (-30.95%)
Ronald Muhlenkamp 106,645 sh (-55.54%)
David Tepper 2,175,000 sh (-56.96%)
Richard Snow 73,227 sh (-61.80%)
» More
Q2 2017

TEVA Guru Trades in Q2 2017

Manning & Napier Advisors, Inc Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TEVA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF584.0011.977 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:NYSE:TARO, NAS:STDY, OTCPK:OWCP » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVJF.USA,
Headquarter Location:Israel
Teva Pharmaceutical Industries Ltd is a pharmaceutical company which develops, produces and markets generic and specialty medicines which include chemical and therapeutic medicines in a variety of dosage forms and central nervous system medicines.

Headquartered in Israel, Teva Pharmaceutical is the world's largest generic pharmaceutical manufacturer. The company also develops and sells branded pharmaceuticals in central nervous system, oncology, respiratory, and women's health categories. After acquiring Allergan's generics business, Teva's generic sales should be over 60% of total revenue, with branded drug and international over-the-counter revenue making up the balance of sales. Copaxone makes up about half of Teva's branded drug segment, with about $4 billion in sales for 2015.

Guru Investment Theses on Teva Pharmaceutical Industries Ltd

John Keeley Comments on Teva Pharmaceuticals - Apr 26, 2016

Teva Pharmaceuticals (NYSE:TEVA) also had a challenging quarter. Although earnings were in-line with expectations, the company announced that its acquisition of Allergan’s generic pharmaceutical business would be delayed. Subsequent to the failure of the Pfizer/Allergan merger due to the proposed tax inversion regulatory changes, Teva announced that its acquisition of Allergan’s generic business remains on track to close in the second quarter of 2016.



From Keeley All Cap Value Fund first quarter 2016 commentary.



Check out John Keeley latest stock trades

Bernard Horn Comments on Teva Pharmaceutical - Mar 21, 2016

Teva Pharmaceutical (NYSE:TEVA) achieved strong profits, noting better-than-expected Copaxone sales. The company’s strategic initiatives, including the takeover of Allergan’s Actavis generic drug business and the joint venture with Takeda in Japan, were well received. This will further cement Teva’s position as the global leader in generics and help the company negotiate with its customers.

From Bernard Horn (Trades, Portfolio)'s Global Value Fund annual letter 2015.



Check out Bernard Horn latest stock trades

Top Ranked Articles about Teva Pharmaceutical Industries Ltd

The Fading Fortunes of John Paulson Hedge fund guru won attention for his strategy during the subprime crisis, but lately he’s been getting attention for the wrong reasons
John Paulson (Trades, Portfolio) was once a darling of Wall Street, having handsomely profited because of his smart bets on the subprime crisis while many of his counterparts suffered. Read more...
Francis Chou Buys Pharmaceutical Stocks, Including Valeant Chou said he is making a 'basket' of the 'attractive' stocks
Francis Chou (Trades, Portfolio)’s Toronto-based fund announced this week that it bought two new drug manufacturers in the first quarter, along with adding to stakes in oil and gas and a notoriously troubled pharmaceutical company. Read more...
Stocks That Fell to 3-Year Lows in the Week of April 14 Teva Pharmaceutical Industries Ltd, Nielsen Holdings PLC, Perrigo Co PLC, and Kimco Realty Corp fell to their respective three-year lows.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA), Nielsen Holdings PLC (NYSE:NLSN), Perrigo Co PLC (NYSE:PRGO), and Kimco Realty Corp (NYSE:KIM) have declined to their three-year lows. Read more...
What Will Make Man Smarter? Companies are increasingly investing in smart drugs
The word "smart" has become a mainstay in every culture across the globe due to the increased use of smart devices. Yet the biggest challenge is making sure that man can keep up with the advances in technology. Are you afraid of AI? Read more...
Risk-Reward With Teva Pharmaceutical With the stock down close to 40% over the last year, is it a buy or a value trap?
As two of its largest guru shareholders, John Paulson (TradesPortfolio) and David Tepper (TradesPortfolio) are dead wrong on Teva Pharmaceutical Industires Ltd. (NYSE:TEVA). Teva is a value trap even if the stock had a short-term price pop. Paulson owns 15.9 million shares, good for 7.36% of his portfolio, while Tepper owns 5.05 million shares, good for 3.25% of his total assets managed. Read more...
23 Questions With the Founder of WayUndervalued.com Are there other sector companies trading similarly? If not, ask yourself why one company would be different
1. How and why did you get started investing? What is your background? Read more...
Valeant: It's Not a Game of Chess- Part I A case study of the rise and fall of Valeant
Who Is Winning the Fight Against Opioid Abuse? A recent survey found approximately 23.5 million Americans are addicted to drugs and alcohol
The extent of the opioid epidemic in the U.S. is so pervasive that the Substance Abuse and Mental Health Services Administration’s (SAMHSA) National Survey on Drug Use and Health estimated that around 23.5 million Americans, aged 12 or older, are addicted to drugs and alcohol. Read more...
David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Naltrexone Showing More Potential in Drug Addiction Treatment Market Teva Pharmaceuticals and Alkermes produce 2 main forms of treatment
In the on-going debate of which drug addiction treatment is more effective, naltrexone is showing more potential than buprenorphine, according to the latest study by researchers from Columbia University. Read more...

Ratios

vs
industry
vs
history
PE Ratio 3247.00
TEVA's PE Ratio is ranked lower than
100% of the 555 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.93 vs. TEVA: 3247.00 )
Ranked among companies with meaningful PE Ratio only.
TEVA' s PE Ratio Range Over the Past 10 Years
Min: 10.49  Med: 20.77 Max: 3470
Current: 3247
10.49
3470
Forward PE Ratio 7.03
TEVA's Forward PE Ratio is ranked higher than
94% of the 67 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.90 vs. TEVA: 7.03 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 3247.00
TEVA's PE Ratio without NRI is ranked lower than
100% of the 554 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.21 vs. TEVA: 3247.00 )
Ranked among companies with meaningful PE Ratio without NRI only.
TEVA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.49  Med: 20.77 Max: 3470
Current: 3247
10.49
3470
Price-to-Owner-Earnings 20.05
TEVA's Price-to-Owner-Earnings is ranked higher than
70% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.90 vs. TEVA: 20.05 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
TEVA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.09  Med: 16.38 Max: 72.38
Current: 20.05
9.09
72.38
PB Ratio 1.09
TEVA's PB Ratio is ranked higher than
86% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. TEVA: 1.09 )
Ranked among companies with meaningful PB Ratio only.
TEVA' s PB Ratio Range Over the Past 10 Years
Min: 0.95  Med: 2.1 Max: 2.91
Current: 1.09
0.95
2.91
PS Ratio 1.42
TEVA's PS Ratio is ranked higher than
75% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. TEVA: 1.42 )
Ranked among companies with meaningful PS Ratio only.
TEVA' s PS Ratio Range Over the Past 10 Years
Min: 1.24  Med: 2.59 Max: 4.33
Current: 1.42
1.24
4.33
Price-to-Free-Cash-Flow 9.39
TEVA's Price-to-Free-Cash-Flow is ranked higher than
87% of the 208 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.89 vs. TEVA: 9.39 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
TEVA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.15  Med: 13.7 Max: 32.03
Current: 9.39
7.15
32.03
Price-to-Operating-Cash-Flow 7.40
TEVA's Price-to-Operating-Cash-Flow is ranked higher than
86% of the 277 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.02 vs. TEVA: 7.40 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
TEVA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.93  Med: 10.61 Max: 22.47
Current: 7.4
5.93
22.47
EV-to-EBIT 65.56
TEVA's EV-to-EBIT is ranked lower than
89% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. TEVA: 65.56 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVA' s EV-to-EBIT Range Over the Past 10 Years
Min: 12  Med: 20.9 Max: 114.5
Current: 65.56
12
114.5
EV-to-EBITDA 25.76
TEVA's EV-to-EBITDA is ranked lower than
69% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. TEVA: 25.76 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.1  Med: 14.8 Max: 39.4
Current: 25.76
9.1
39.4
Shiller PE Ratio 13.97
TEVA's Shiller PE Ratio is ranked higher than
91% of the 198 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.37 vs. TEVA: 13.97 )
Ranked among companies with meaningful Shiller PE Ratio only.
TEVA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.23  Med: 26.54 Max: 60.19
Current: 13.97
12.23
60.19
Current Ratio 0.93
TEVA's Current Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVA: 0.93 )
Ranked among companies with meaningful Current Ratio only.
TEVA' s Current Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.59 Max: 2.95
Current: 0.93
0.9
2.95
Quick Ratio 0.62
TEVA's Quick Ratio is ranked lower than
91% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. TEVA: 0.62 )
Ranked among companies with meaningful Quick Ratio only.
TEVA' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.04 Max: 2.19
Current: 0.62
0.62
2.19
Days Inventory 156.20
TEVA's Days Inventory is ranked lower than
69% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. TEVA: 156.20 )
Ranked among companies with meaningful Days Inventory only.
TEVA' s Days Inventory Range Over the Past 10 Years
Min: 156.2  Med: 186.4 Max: 208.14
Current: 156.2
156.2
208.14
Days Sales Outstanding 116.68
TEVA's Days Sales Outstanding is ranked lower than
75% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. TEVA: 116.68 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 116.68
95.91
153.21
Days Payable 80.10
TEVA's Days Payable is ranked higher than
57% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. TEVA: 80.10 )
Ranked among companies with meaningful Days Payable only.
TEVA' s Days Payable Range Over the Past 10 Years
Min: 78.39  Med: 84.39 Max: 111.41
Current: 80.1
78.39
111.41

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 4.18
TEVA's Dividend Yield % is ranked higher than
94% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. TEVA: 4.18 )
Ranked among companies with meaningful Dividend Yield % only.
TEVA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.66  Med: 2.08 Max: 4.77
Current: 4.18
0.66
4.77
Dividend Payout Ratio 68.00
TEVA's Dividend Payout Ratio is ranked lower than
100% of the 406 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.33 vs. TEVA: 68.00 )
Ranked among companies with meaningful Dividend Payout Ratio only.
TEVA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.42 Max: 68
Current: 68
0.14
68
3-Year Dividend Growth Rate 2.00
TEVA's 3-Year Dividend Growth Rate is ranked lower than
63% of the 299 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.90 vs. TEVA: 2.00 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
TEVA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -6.7  Med: 23.6 Max: 80.9
Current: 2
-6.7
80.9
Forward Dividend Yield % 4.17
TEVA's Forward Dividend Yield % is ranked higher than
93% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TEVA: 4.17 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 6.43
TEVA's 5-Year Yield-on-Cost % is ranked higher than
92% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. TEVA: 6.43 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
TEVA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.02  Med: 3.2 Max: 7.34
Current: 6.43
1.02
7.34
3-Year Average Share Buyback Ratio -2.30
TEVA's 3-Year Average Share Buyback Ratio is ranked higher than
60% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. TEVA: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TEVA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.6  Med: -2.3 Max: 4.6
Current: -2.3
-12.6
4.6

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.54
TEVA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
94% of the 328 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. TEVA: 0.54 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
TEVA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.53  Med: 1.57 Max: 11.3
Current: 0.54
0.53
11.3
Price-to-Median-PS-Value 0.54
TEVA's Price-to-Median-PS-Value is ranked higher than
90% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. TEVA: 0.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
TEVA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.34  Med: 1.07 Max: 2.25
Current: 0.54
0.34
2.25
Earnings Yield (Greenblatt) % 1.53
TEVA's Earnings Yield (Greenblatt) % is ranked lower than
62% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TEVA: 1.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
TEVA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.9  Med: 4.8 Max: 8.4
Current: 1.53
0.9
8.4
Forward Rate of Return (Yacktman) % 8.56
TEVA's Forward Rate of Return (Yacktman) % is ranked lower than
58% of the 380 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. TEVA: 8.56 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
TEVA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7.8  Med: 18.3 Max: 46
Current: 8.56
7.8
46

More Statistics

Revenue (TTM) (Mil) $22,723.00
EPS (TTM) $ 0.01
Beta0.49
Short Percentage of Float0.00%
52-Week Range $27.60 - 55.79
Shares Outstanding (Mil)1,016.00 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 23,249 23,019 23,696
EPS ($) 4.67 4.60 5.17
EPS without NRI ($) 4.67 4.60 5.17
EPS Growth Rate
(Future 3Y To 5Y Estimate)
0.33%
Dividends per Share ($) 1.36 1.43 1.65
» More Articles for TEVA

Headlines

Articles On GuruFocus.com
The World's Largest Generic Drugmaker Is Plunging Jul 19 2017 
The Fading Fortunes of John Paulson Jun 08 2017 
Francis Chou Buys Pharmaceutical Stocks, Including Valeant May 17 2017 
Stocks That Fell to 3-Year Lows in the Week of April 14 Apr 22 2017 
What Will Make Man Smarter? Apr 10 2017 
Risk-Reward With Teva Pharmaceutical Mar 27 2017 
23 Questions With the Founder of WayUndervalued.com Mar 26 2017 
Valeant: It's Not a Game of Chess Part I Mar 16 2017 
Who Is Winning the Fight Against Opioid Abuse? Feb 27 2017 
David Tepper Invests Heavily in Pharma in 4th Quarter Feb 16 2017 

More From Other Websites
Teva Announces the Launch of Generic Vagifem® in the United States Jul 24 2017
Teva Pharm to reduce workforce in Israel, mainly in production Jul 23 2017
Stull, Stull & Brody Announces Class Action Lawsuit on Behalf of Employee Benefit Plan Purchasers of... Jul 21 2017
7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods Jul 21 2017
AstraZeneca CEO reassures staff, aims to be at September cancer meet Jul 21 2017
Mount Vernon Associates Inc Buys Energy Transfer Partners LP, Teva Pharmaceutical Industries Jul 20 2017
NICE Recommends CINQAERO® (reslizumab) for the Treatment of Severe Eosinophilic Asthma Jul 20 2017
AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise Jul 17 2017
[$$] EU accuses Teva Pharmaceutical of anti-competitive behaviour Jul 17 2017
U.S. court upholds Takeda patent on cancer drug Velcade Jul 17 2017
Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Coming Back Jul 17 2017
Valeant Unloads Yet Another Unit Jul 17 2017
EU regulators charge Teva over pay-for-delay drug deal Jul 17 2017
AstraZeneca Shares Top FTSE 100 After Drugmaker Says CEO Will Host Late-July Earnings Call Jul 17 2017
Here Are The 5 Stories Europe Was Talking About This Week Jul 14 2017
[$$] AstraZeneca CEO's Future Remains Shrouded in Mystery Jul 14 2017
[$$] Pascal Soriot to remain at AstraZeneca Jul 14 2017
Why Cyberark Software Ltd (CYBR), Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Wynn Resorts,... Jul 14 2017
AstraZeneca Pops On Report CEO Won't Jump Ship For Teva Pharma Jul 14 2017
Potential AstraZeneca C-Suite Shuffle Rekindles Takeover Chatter Jul 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}